ARS Pharmaceuticals, Inc. (SPRY) bonds
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.65+0.06 (+1.67%)
Close on Nov 17, 2026Market cap $362.98MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
ARS Pharmaceuticals reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in ARS Pharmaceuticals's 10-Q for the period ended Sep 29, 2025
| Issue | Coupon | Matures | Amount issued |
|---|---|---|---|
| Term Loans | 3.00% | Sep 29, 2030 | $250.00M |
| Tranche Four Term Loan | – | – | $100.00M |
| Tranche One Term Loan | – | – | $100.00M |
| Tranche Three Term Loan | – | – | $25.00M |
| Tranche Two Term Loan | – | – | $25.00M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?